Xilio Therapeutics (XLO) Cash from Operations (2020 - 2026)

Xilio Therapeutics has disclosed Cash from Operations across 7 years of filings, most recently posting 22343000.0 for Q1 2026.

• Cash from Operations for Q1 2026 came in at 22343000.0, down 177.1% year-over-year; the trailing twelve-month figure through Mar 2026 was 56313000.0 (down 366.86% YoY), and the FY2025 annual result was 4992000.0, up 72.84% from the prior year.
• Cash from Operations came in at 22343000.0 for Q1 2026 at Xilio Therapeutics, down from 1998000.0 in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of 28978000.0 in Q1 2025 to a low of 25250000.0 in Q1 2023.
• The 5-year median for Cash from Operations is 14477000.0 (2025), against an average of 11179764.71.
• Across the five-year window, Cash from Operations soared 375.93% in 2025 and sank 177.1% in 2026, its largest moves.
• Xilio Therapeutics' Cash from Operations stood at 18223000.0 in 2022, then gained by 26.32% to 13427000.0 in 2023, then slipped by 5.44% to 14157000.0 in 2024, then surged by 85.89% to 1998000.0 in 2025, then sank by 1018.27% to 22343000.0 in 2026.
• The last three Cash from Operations figures came in at 22343000.0 (Q1 2026), 1998000.0 (Q4 2025), and 17495000.0 (Q3 2025), per Business Quant data.